Literature DB >> 12751634

Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1).

Kavitha Koushik1, Gangadhar Sunkara, Peter Gwilt, Uday B Kompella.   

Abstract

PURPOSE: The objective of this study is to investigate the pathways and kinetics of degradation of deslorelin, pGlu1-His2-Trp3-Ser4-Tyr5-D-Trp6-Leu7-Arg8-ProNHEt9 (Des1-9), in a human airway epithelial cell line (Calu-1).
METHODS: The degradation of deslorelin in membrane and cytosolic fractions of Calu-1 cells was studied at 37 degrees C up to 24 h. The degradation products were separated using HPLC and identified by amino acid analysis, sequencing, and mass spectrometry. The rate constants for deslorelin degradation and the formation of degradation products were determined by fitting the concentration vs. time data to pharmacokinetic models using WinNonlin. The effect of enzyme inhibitors, captopril, phosphoramidon, and disodium EDTA on deslorelin degradation was also assessed.
RESULTS: Des1-3, Des4-9, and Des5-9 were the deslorelin fragments detected in the membrane fraction. Apart from these degradation products. Des5-7 was also detected in the cytosolic fraction. The deslorelin degradation was 8.5 times faster in the cytosolic fraction compared to the membrane fraction. The disappearance of deslorelin and the kinetics of degradation products could be explained by simple 2 compartment iv bolus model and 1 compartment absorption model, respectively. EDTA and captopril decreased deslorelin degradation in the membrane and cytosolic fractions.
CONCLUSIONS: Deslorelin is initially cleaved at the 3-4 bond in the membrane and cytosolic fractions, possibly by a metalloendopeptidase and/or angiotensin converting enzyme, with the degradation being more rapid in the cytosol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751634     DOI: 10.1023/a:1023489620394

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.

Authors:  Gabor Halmos; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

3.  Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit conjunctiva.

Authors:  U B Kompella; B A Dani
Journal:  J Ocul Pharmacol Ther       Date:  1997-04       Impact factor: 2.671

4.  Inhibition of corneal metabolism of deslorelin by EDTA and ZnCl2.

Authors:  B A Dani; U B Kompella
Journal:  Drug Dev Ind Pharm       Date:  1998-01       Impact factor: 3.225

5.  Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPbetaCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin.

Authors:  K N Koushik; N Bandi; U B Kompella
Journal:  Pharm Dev Technol       Date:  2001-11       Impact factor: 3.133

6.  Metabolism of [Des-Gly10,D-Trp6]LHRH ethylamide in rabbit nasal tissue.

Authors:  U B Kompella; B A Dani
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

Review 7.  The facts about fibroids. Presentation and latest management options.

Authors:  J K Christiansen
Journal:  Postgrad Med       Date:  1993-09-01       Impact factor: 3.840

8.  Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.

Authors:  A Lasdun; S Reznik; C J Molineaux; M Orlowski
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

9.  Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages.

Authors:  H L Jackman; F Tan; D Schraufnagel; T Dragović; B Dezsö; R P Becker; E G Erdös
Journal:  Am J Respir Cell Mol Biol       Date:  1995-08       Impact factor: 6.914

10.  Two novel monoclonal antibodies against the MUC4 tandem repeat reacting with an antigen overexpressed by lung cancer.

Authors:  C Botti; E Seregni; S Ménard; P Collini; E Tagliabue; M Campiglio; B Vergani; C Ghirelli; P Aiello; S Pilotti; E Bombardieri
Journal:  Int J Biol Markers       Date:  2000 Oct-Dec       Impact factor: 3.248

View more
  2 in total

1.  Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist.

Authors:  Kavitha Koushik; Nagesh Bandi; Sneha Sundaram; Uday B Kompella
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

2.  Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.

Authors:  Kavitha Koushik; Devender S Dhanda; Narayan P S Cheruvu; Uday B Kompella
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.